tripelennamine
Approved
Feb 19, 1948
Tripelennamine (sold as Pyribenzamine by Novartis) is a drug that is used as an antipruritic and first-generation antihistamine. Histamine acting on H1-receptors produces vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Tripelennamine can be used in the treatment of asthma, hay fever, rhinitis, and urticaria, but is now less common as newer antihistamines have replaced it. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 10 marketing orgs
Timeline
1940s
- Feb 19, 1948
Earliest FDA Approval
- Feb 19, 1948
Novartis — NDA Secondary Org
1970s
- Sep 27, 1972
Barr Laboratories — Marketing Organization
- Jan 18, 1973
Watson Pharmaceuticals — Marketing Organization
- Sep 6, 1973
Novartis — Marketing Organization
- May 10, 1974
Lannett Company, Inc. — Marketing Organization
Indications
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Approval history
- approvedFeb 19, 1948
Chemistry & pharmacology
SMILES
CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2- Mol. weight
- 255.358 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaTripelennamine ↗
- NCATS3C5ORO99TY ↗
- ChEMBLCHEMBL1241 ↗
- ChEMBLCHEMBL1200769 ↗
- ChEMBLCHEMBL1200446 ↗
Also known as
- pbz
- pbz
- pbz-sr
- pbz-sr
- pyribenzamin
- pyribenzamine
- pyrinamine base
- tripelenamine
- tripelennamin
- tripelennamin
- tripelennamin
- tripelennamin
- tripelennamina
- tripelennamina
- tripelennamine
- tripelennamine
- tripelennamine
- tripelennamine
- tripelennamine
- tripelennamine
- tripelennamine
- tripelennamine
- tripélennamine
- tripélennamine
- tripelennamine chloride
- tripelennamine chloride
- tripelennamine citrate
- tripelennamine citrate
- tripelennamine citrate
- tripelennamine citrate
- tripelennamine hcl
- tripelennamine hcl
- tripelennamine hcl
- tripelennamine hydrochloride
- tripelennamine hydrochloride
- tripelennamine hydrochloride
- tripelennamine hydrochloride
- tripelennaminum
- tripelennaminum
Organizations
Marketing (11)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Anabolic Pharma | Academic/Hospital | MKTG | — |
| Barr Laboratories | For profit | MKTG | Sep 27, 1972 |
| Ciba | For profit | NDA | — |
| Heather Pharma | For profit | MKTG | — |
| Impax Laboratories | For profit | MKTG | — |
| Lannett Company, Inc. | For profit | MKTG | May 10, 1974 |
| NYLOS | For profit | MKTG | — |
| Novartis | For profit | NDA2 | Feb 19, 1948 |
| Novartis | For profit | MKTG | Sep 6, 1973 |
| Parke-Davis | For profit | MKTG | — |
| Watson Pharmaceuticals | For profit | MKTG | Jan 18, 1973 |